## On the Metabolism of D-Penicillamine

## Felicitas Planas-Bohne

Institut für Strahlenbiologie, Kernforschungszentrum Karlsruhe

(Z. Naturforsch. 28 c, 774 [1973]; received August 9. September 17, 1973)

## D-penicillamine, rat

D-Penicillamine (PA) is a potent drug in the treatment of hepatolenticular degeneration, rheumatoid arthritis, cystinuria and heavy metal poisoning. Much recent interest has centred on its pharmacokinetics. The question of whether PA, being excreted mainly with the urine 1-3, is subject to metabolic transformation and/or degradation, is still open. Milne 4 claims that approx. 50 per cent is degraded to anorganic sulphate. According to other authors 1, 5-7, however, the bulk of PA is excreted as PA-disulphide and as mixed disulphide with cysteine. These contradictory findings prompted us to determine the various urinary sulphur fractions following administration of PA. Some thiols, such as 2,3-dimercapto-propanol 8, are subject to glucuronidation. Therefore, we examined also whether this is true for PA.

Male rats of the Heiligenberg-strain with an average body weight of 150 g were injected intravenously with 10 mmoles PA/kg. This high dosage was not toxic and was chosen in order to get clearcut results. The control animals received physiological saline. As the bulk of PA is excreted within few hours 1, the 6 hours-urine was collected. Sulphur was determined by the method of Kleeman

Requests for reprints should be sent to Dr. Felicitas Planas, Institut für Strahlenbiologie, Kernforschungszentrum Karlsruhe, D-7500 Karlsruhe 1, Postfach 3640.

<sup>1</sup> F. Planas-Bohne, Arzneimittel-Forsch. (Drug Res.) 22, 1426 [1972].

<sup>2</sup> K. Gibbs and J. M. Walshe, Quart. J. Med. XL, 275 [1971].

3 H. Schüßler, Arzneimittel-Forsch. (Drug Res.) 17, 364

<sup>4</sup> M. D. Milne, Annu. Rev. Pharmacol. 5, 119 [1965].

<sup>5</sup> L. Eldjarn and L. Hambraeus, Scand. J. clin. Lab. Invest. 16, 153 [1964].

Table I. Excretion of sulphur compounds and glucuronic acid by rats after administration of D-penicillamine. Arithmetic means ± S.E. 6 rats per group.

	Amounts excreted [mg in 6 hours-urine]	
	Control	PA
neutral sulphur	0.61 + 0.22	17.15 + 3.58
ethereal sulphur	$0.26 \pm 0.17$	$0.17 \pm 0.074$
free sulphate	$2.56 \pm 0.21$	$3.75 \pm 0.65$
glucuronic acid	$15.04\pm2.06$	$14.37 \pm 1.50$

et al. 9, glucuronic acid by the modified method of Maughan 10.

As can be seen from Table I, there is neither an increase of the glucuronic acid nor of the ethereal sulphur. This may be taken as evidence that PA is not subject to glucuronic or sulphuric acid conjugation. The difference between the excreted amounts of anorganic sulphate does not reach statistical significance (P = 0.12). The lacking (or utmost marginal) degradation of PA to free sulphate is in agreement with an in vitro-study 11 showing that the SH-grouping of PA is not attacked by cysteine desulphhydrase. The increase in the neutral sulphur fraction, ascribable to the excretion of the PAdisulphides, amounts to 0.52 mmole, i.e. to 35 per cent of the administered PA-dose. This value is slightly lower than the excretion of 14C-PA after injection of 0.1 mmole/kg 1. However, one must take into acount that there is an inverse relationship between the excretion rate and dosage of PA 1.

From the metabolic point of view, PA is a virtually inert compound; this is easily explained by the fact that the extracellular water is the main dilution space of PA 12.

- <sup>6</sup> J. C. Crawhall and C. J. Thompson, Science [Washington] 147, 1459 [1965]

- B. S. Hartley and J. M. Walshe, Lancet **II**, 434 [1963]. G. H. Spray, Biochem. J. 41, 366 [1947]. C. R. Kleeman, E. Taborsky, and F. H. Epstein, Proc. Soc. exp. Biol. Med. 91, 480 [1956].
- G. B. Maughan, K. A. Evelyn, and J. S. L. Browne, J. biol. Chemistry 126, 567 [1938].
  H. V. Aposhian and L. S. Bradham, Biochem. Pharmacol.
- 3, 38 [1959].
- 12 E. Polig and F. Planas-Bohne, Biophysik in press.

